Abstract
Capuramycin (CM) antibiotics are bactericidal for Mycobacterium tuberculosis (MTB) in vitro. Due to their low membrane permeability and efflux, however, these compounds are less effective against intracellular MTB. To improve intracellular activity, we created phospholipid Phosal 53 MCT-based nanoemulsion (NE) formulations of CM analogues SQ641, SQ641-aua, SQ641-2aua and SQ997-3aua. We assessed intracellular killing activity of the 4 CM analogues and their NE formulations against MTB using the J774A.1 mouse macrophage cell line. Of the several emulsifiers investigated, d-tocopheryl polyethylene glycol 1000 succinate (TPGS) produced the most efficacious and stable emulsion, with a mean particle size below 70 nm. CM analogue-NE formulations prepared using TPGS as emulsifier (-NETPGS) showed significantly improved intracellular activity over free drugs. The order of intracellular activity was SQ641-2aua- NETPGS > SQ997-3aua-NETPGS > SQ641-aua-NETPGS > SQ641-NETPGS. At 2× MIC the intracellular killing activity of SQ641- 2aua-NETPGS, the most active formulation, surpassed that of first-line anti-TB drugs isoniazid (INH), rifampin (RIF) and ethambutol (EMB). Enhanced intracellular activity of the -NETPGS formulation, perhaps, was due to TPGS mediated blocking of the drug efflux.
Keywords: Anti-TB drugs, SQ641, phospholipids, nanoemulsion, M.tuberculosis, intracellular activity, capuramycin, Intracellular Drug Activity, CM Analogues, emulsifiers
Drug Delivery Letters
Title: Nanoemulsion Formulation Enhances Intracellular Activity of Capuramycin Analogues against Mycobacterium Tuberculosis
Volume: 1 Issue: 2
Author(s): Venkata M. Reddy, Elena Bogatcheva, Leo Einck and Carol A. Nacy
Affiliation:
Keywords: Anti-TB drugs, SQ641, phospholipids, nanoemulsion, M.tuberculosis, intracellular activity, capuramycin, Intracellular Drug Activity, CM Analogues, emulsifiers
Abstract: Capuramycin (CM) antibiotics are bactericidal for Mycobacterium tuberculosis (MTB) in vitro. Due to their low membrane permeability and efflux, however, these compounds are less effective against intracellular MTB. To improve intracellular activity, we created phospholipid Phosal 53 MCT-based nanoemulsion (NE) formulations of CM analogues SQ641, SQ641-aua, SQ641-2aua and SQ997-3aua. We assessed intracellular killing activity of the 4 CM analogues and their NE formulations against MTB using the J774A.1 mouse macrophage cell line. Of the several emulsifiers investigated, d-tocopheryl polyethylene glycol 1000 succinate (TPGS) produced the most efficacious and stable emulsion, with a mean particle size below 70 nm. CM analogue-NE formulations prepared using TPGS as emulsifier (-NETPGS) showed significantly improved intracellular activity over free drugs. The order of intracellular activity was SQ641-2aua- NETPGS > SQ997-3aua-NETPGS > SQ641-aua-NETPGS > SQ641-NETPGS. At 2× MIC the intracellular killing activity of SQ641- 2aua-NETPGS, the most active formulation, surpassed that of first-line anti-TB drugs isoniazid (INH), rifampin (RIF) and ethambutol (EMB). Enhanced intracellular activity of the -NETPGS formulation, perhaps, was due to TPGS mediated blocking of the drug efflux.
Export Options
About this article
Cite this article as:
M. Reddy Venkata, Bogatcheva Elena, Einck Leo and A. Nacy Carol, Nanoemulsion Formulation Enhances Intracellular Activity of Capuramycin Analogues against Mycobacterium Tuberculosis, Drug Delivery Letters 2011; 1 (2) . https://dx.doi.org/10.2174/2210304x11101020150
DOI https://dx.doi.org/10.2174/2210304x11101020150 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Invasive Biomarkers of Lung Inflammation in Smoking Subjects
Current Medicinal Chemistry Recent Advances in New Structural Classes of Anti-Tuberculosis Agents
Current Medicinal Chemistry Health Benefits of Ipecac and Cephaeline: their Potential in Health Promotion and Disease Prevention
Current Bioactive Compounds Malononitrile as a Key Reagent in Multicomponent Reactions for the Synthesis of Pharmaceutically Important Pyridines
Current Organic Chemistry Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Therapeutic Potential of Indole Derivatives as Anti-HIV Agents: A Mini-review
Current Topics in Medicinal Chemistry Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Lignans and Neolignans Anti-tuberculosis Identified by QSAR and Molecular Modeling
Combinatorial Chemistry & High Throughput Screening Patent Annotations
Recent Patents on Anti-Infective Drug Discovery The TLR4 ASP299GLY Polymorphism is a Risk Factor for Active Tuberculosis in Caucasian HIV-Infected Patients
Current HIV Research Antibacterial Activity and Structure-activity Relationship Studies of 4- substituted-5-(diphenylmethyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones
Letters in Drug Design & Discovery Nitazoxanide Analogues as Antimicrobial Agents Against Nosocomial Pathogens
Medicinal Chemistry Iron Chelation as Therapy for HIV and Mycobacterium tuberculosis Co-Infection Under Conditions of Iron Overload
Current Pharmaceutical Design Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds
Current Organic Chemistry Mesenchymal Stem Cells: A New Generation of Therapeutic Agents as Vehicles in Gene Therapy
Current Gene Therapy State of the Art of Nanobiotechnology Applications in Neglected Diseases
Current Nanoscience In Silico Discovery and Virtual Screening of Multi-Target Inhibitors for Proteins in Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews